Featured in June: Chronic Constipation, ILC, DDW

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Healio Gastroenterology presents the following report on the best peer-tested stories in June.

These stories include reports on the management of chronic constipation, treatment of inflammatory bowel disease, and research presented at the International Liver Conference as well as Digestive Disease Week.

Kiwifruit effectively relieves symptoms of chronic constipation

Patients with chronic constipation who were given kiwi fruit, prunes and psyllium reported symptom relief, according to a study published in American Journal of Gastroenterology.

“Patients are increasingly looking for evidence-based natural treatments for many medical conditions, including [chronic constipation (CC)], ” Samuel W. Chey, MPH, from the University of Michigan and colleagues wrote. “Many patients believe that natural products are safer and less expensive than prescription drugs. In this sense, so-called “functional foods” are gaining popularity. This study confirms the benefits of prunes and psyllium and offers the first US data on green kiwifruit as a safe, effective and well-tolerated treatment for a subset of patients with CC. READ MORE.

Combination therapy commonly used with Entyvio, Stelara

Entyvio and Stelara have been commonly used in combination therapy for the treatment of inflammatory bowel disease, according to a study by Digestive Disease Week.

“When used with an immunomodulator (ie, azathioprine, methotrexate), anti-TNFs are associated with lower levels of anti-drug antibodies and increased rates of remission clinical, but also to increased rates of infections. ” Megan Lutz, MD, researcher at the School of Medicine and Public Health at the University of Wisconsin, said Healio Gastroenterology. “[Entyvio (vedolizumab, Takeda)] and [Stelara (ustekinumab, Janssen)] are newer biological therapies that do not appear to carry the same risk of infection as anti-TNF or immunomodulators. A growing body of evidence also suggests that these newer biologics have lower levels of immunogenicity and are not necessarily more effective when used with an immunomodulator. Further prospective data are needed to determine efficacy and minimize risk for patients starting combination therapy with vedolizumab or ustekinumab for IBD. READ MORE.

Low-carb, high-fat, intermittent fasting diets further reduce fatty liver disease in NAFLD

Researchers found greater reduction in steatosis and body weight with low-carbohydrate, high-fat, and 5: 2 diets compared to standard care in patients with non-alcoholic fatty liver disease, according to a presentation at the International Congress liver.

“5: 2 and [low-carb high-fat (LCHF)] the diets were equally effective in the short-term reduction of fatty liver disease, body weight and insulin resistance measured in NAFLD ”, Magnus Holmer, MD, from the Department of Medicine at the Karolinska Institute in Stockholm, Sweden, said during his presentation. “From the strong correlation between reduction in fatty liver disease and body weight, we conclude that the weight reduction itself and not the macronutrient composition which is crucial for successful dietary therapy in NAFLD.” READ MORE.

Average monthly hospital admissions for alcoholic hepatitis increases 9% after COVID-19

Although the monthly admission rates before and after COVID-19 are stable for non-alcoholic and alcoholic cirrhosis; admissions of alcoholic hepatitis have increased, according to a presentation at the International Liver Congress.

“Our results actually show that an increase in alcohol sales after the pandemic will have a significant impact on the natural history of alcohol-related liver disease in Canada and probably in most Western countries,” a- he added. Abdel Aziz Shaheen, MD, from the Cumming School of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Canada, said during his presentation. READ MORE.

Younger age at screening linked to lower incidence of CRC

Endoscopy in patients under the age of 50 decreased the incidence of colorectal cancer, according to study estimates reported during Digestive Disease Week.

“Unlike an overall decline in the incidence of CRC in the United States, there has been a dramatic increase in the incidence of CRC in young adults. … Recently, the American Cancer Society and the US Preventive Services Task Force updated their recommendations to initiate screening for CRC at age 45, primarily based on modeling studies explaining the incidence increase in CRC among young adults ”, Wenjie Ma, D.Sc., the Clinical and Translational Epidemiology Unit and Division of Gastroenterology at Massachusetts General Hospital and Harvard Medical School, and colleagues have written. “However, to date, there is little empirical evidence evaluating the potential benefits of screening in younger populations.” READ MORE.

Q&A: Trulance improves quality of life in chronic constipation, IBS-C

Researchers observed clinically and statistically significant improvements with Trulance in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation and reduced quality of life.

The results were presented at the national conference of the American Association of Nurse Practitioners. READ MORE.

SARS-CoV-2 Impacts Long-Term Brain-Gut Axis

SARS-CoV-2 could have a lasting impact on the brain-gut axis, according to a presentation at Digestive Disease Week.

“Bacterial, protozoan and viral infections of the gastrointestinal tract are known to represent a risk factor for the development of functional gastrointestinal disorders such as irritable bowel syndrome and functional dyspepsia, as well as chronic fatigue and fatigue. other extra-intestinal symptoms such as somatoform disorders. Daniele Noviello, MD, University of Milan, said. “In February 2020, an outbreak of SARS-CoV-2 occurred in Italy with extreme severity in Milan; this provided us with a unique opportunity to assess the long-term impact of SARS-CoV-2, a previously unknown viral infection, on the burden of gastrointestinal and extra-intestinal symptoms. READ MORE.

Stay up to date on all the latest gastroenterology research by following @HealioGastro on Twitter.

Back To Top